Frank Andersohn1,2, Jochen Walker3,4. 1. Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, Berlin, Germany. 2. Frank Andersohn Consulting & Research Services, Berlin, Germany. 3. Elsevier GmbH, Munich, Germany. 4. Health Risk Institute GmbH, Berlin, Germany.
Abstract
PURPOSE: The aim of this study was to describe characteristics and external validity of the German Health Risk Institute (HRI) Database. METHODS: The HRI Database is an anonymized healthcare database with longitudinal data from approximately six Mio Germans. In addition to demographic information (gender, age, region of residence), data on persistence of insurants over time, hospitalization rates, mortality rates and drug prescription rates were extracted from the HRI database for 2013. Corresponding national reference data were obtained from official sources. RESULTS: The proportion of men and women was similar in the HRI Database and Germany, but the database population was slightly younger (mean 40.4 vs 43.7 years). The proportion of insurants living in the eastern part of Germany was lower in the HRI Database (10.1% vs 19.7%). There was good accordance to German reference data with respect to hospitalization rates, overall mortality rate and prescription rates for the 20 most often reimbursed drug classes, with the overall burden of morbidity being slightly lower in the HRI database. From insurants insured on 1 January 2009 (N = 6.2 Mio), a total of 70.6% survived and remained continuously insured with the same statutory health insurance until 31 December 2013. This proportion increased to 77.5% if only insurants ≥40 years were considered. CONCLUSIONS: There was good overall accordance of the HRI database and the German population in terms of measures of morbidity, mortality and drug usage. Persistence of insurants with the database over time was high, indicating suitability of the data source for longitudinal epidemiological analyses.
PURPOSE: The aim of this study was to describe characteristics and external validity of the German Health Risk Institute (HRI) Database. METHODS: The HRI Database is an anonymized healthcare database with longitudinal data from approximately six Mio Germans. In addition to demographic information (gender, age, region of residence), data on persistence of insurants over time, hospitalization rates, mortality rates and drug prescription rates were extracted from the HRI database for 2013. Corresponding national reference data were obtained from official sources. RESULTS: The proportion of men and women was similar in the HRI Database and Germany, but the database population was slightly younger (mean 40.4 vs 43.7 years). The proportion of insurants living in the eastern part of Germany was lower in the HRI Database (10.1% vs 19.7%). There was good accordance to German reference data with respect to hospitalization rates, overall mortality rate and prescription rates for the 20 most often reimbursed drug classes, with the overall burden of morbidity being slightly lower in the HRI database. From insurants insured on 1 January 2009 (N = 6.2 Mio), a total of 70.6% survived and remained continuously insured with the same statutory health insurance until 31 December 2013. This proportion increased to 77.5% if only insurants ≥40 years were considered. CONCLUSIONS: There was good overall accordance of the HRI database and the German population in terms of measures of morbidity, mortality and drug usage. Persistence of insurants with the database over time was high, indicating suitability of the data source for longitudinal epidemiological analyses.
Authors: Andreas D Meid; Andreas Groll; Ulrich Schieborr; Jochen Walker; Walter E Haefeli Journal: Eur J Clin Pharmacol Date: 2016-12-24 Impact factor: 2.953
Authors: Emily Holthuis; Elisabeth Smits; George Spentzouris; Dominik Beier; Dirk Enders; Rosa Gini; Claudia Bartolini; Giampiero Mazzaglia; Fernie Penning-van Beest; Ron Herings Journal: Drugs Real World Outcomes Date: 2022-07-05
Authors: Friedrich Trefz; Ania C Muntau; Kim M Schneider; Julia Altevers; Christian Jacob; Sebastian Braun; Wolfgang Greiner; Ashok Jha; Mohit Jain; Ignacio Alvarez; Paul Lane; Claudia Zeiss; Frank Rutsch Journal: Mol Genet Metab Rep Date: 2021-05-13